➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
McKinsey
Boehringer Ingelheim
Merck
Express Scripts

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TAK-418

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Clinical Trials for TAK-418

Trial ID Title Status Sponsor Phase Summary
NCT00034281 Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 Completed Takeda Phase 1 The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.
NCT00143611 Efficacy & Safety of Resatorvid in Adults With Severe Sepsis Completed Takeda Phase 3 The purpose of this study is to determine the optimal dose of Resatorvid for reducing 28-day all-cause mortality in subjects with severe sepsis.
NCT00143663 Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol Completed Takeda Phase 3 The purpose of this study is to determine if patients with elevated cholesterol, but not taking any other lipid medication, could lower their cholesterol with administration of lapaquistat acetate, once daily (QD).
NCT00143676 Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia Completed Takeda Phase 3 The purpose of this study is to determine the efficacy of lapaquistat acetate, once daily (QD), on lowering cholesterol in subjects already taking atorvastatin.
NCT00229437 Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy Completed Takeda Phase 2 The purpose of this study is to determine the efficacy and safety of TAK-128, once daily (QD), in treating subjects with diabetic peripheral neuropathy.
NCT00251693 Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis Completed Takeda Phase 3 The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for TAK-418

Condition Name

Condition Name for
Intervention Trials
Healthy Volunteers 40
Hypertension 16
Prostate Cancer 14
Diabetes Mellitus 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Diabetes Mellitus 30
Hypertension 26
Diabetes Mellitus, Type 2 21
Prostatic Neoplasms 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for TAK-418

Trials by Country

Trials by Country for
Location Trials
Japan 597
China 90
Canada 81
United Kingdom 68
Mexico 63
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
Texas 85
California 82
Florida 67
Ohio 64
New York 57
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for TAK-418

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 4 4
Phase 3 100
Phase 2/Phase 3 2
[disabled in preview] 225
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 147
Not yet recruiting 86
Recruiting 49
[disabled in preview] 46
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for TAK-418

Sponsor Name

Sponsor Name for
Sponsor Trials
Takeda 230
Millennium Pharmaceuticals, Inc. 78
National Cancer Institute (NCI) 14
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 318
Other 42
NIH 16
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Baxter
Express Scripts
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.